Evidence map›Paper›PMID 23823708›Full record

ArticlePloS one2013

Crystal Structure of Crataeva tapia Bark Protein (CrataBL) and Its Effect in Human Prostate Cancer Cell Lines.

Rodrigo da Silva Ferreira, Dongwen Zhou, Joana Gasperazzo Ferreira, Mariana Cristina Cabral Silva, Rosemeire Aparecida Silva-Lucca, Reinhard Mentele, Edgar Julian Paredes-Gamero, Thiago Carlos Bertolin, Maria Tereza Dos Santos Correia, Patrícia Maria Guedes Paiva and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 36 citations in OpenAlex.

  1. Evaluation of Anti-cancer Potential ofProtein and peptide letters · 2025
    Article
  2. Article
  3. Impairment of SK-MEL-28 Development-A Human Melanoma Cell Line-By theInternational journal of molecular sciences · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. The Plant Proteinase InhibitorBioMed research international · 2018
    Article
  9. Article
  10. Article
  11. Structure of BbKI, a disulfide-free plasma kallikrein inhibitor.Acta crystallographica. Section F, Structural biology communications · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 3 countries.

Rodrigo da Silva FerreiraDepartamento de Bioquímica, Universidade Federal de São Paulo, São Paulo, São Paulo, Brazil.
Dongwen Zhou
Joana Gasperazzo Ferreira
Mariana Cristina Cabral Silva
Rosemeire Aparecida Silva-Lucca
Reinhard Mentele
Edgar Julian Paredes-Gamero
Thiago Carlos Bertolin
Maria Tereza Dos Santos Correia
Patrícia Maria Guedes Paiva
Alla Gustchina
Alexander Wlodawer
Maria Luiza Vilela Oliva
Universidade Federal de São Paulo · BRUniversidade Federal de Pernambuco · BRCenter for Cancer Research · USFrederick National Laboratory for Cancer Research · USLudwig-Maximilians-Universität München · DENational Cancer Institute · USUniversidade Estadual do Oeste do Paraná · BR

Funding

Protein StructureZIABC010348 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WLODAWER, ALEXANDER · 2009 to 2025
$27.5M
6 · The paper itself

Abstract

A protein isolated from the bark of Crataeva tapia (CrataBL) is both a Kunitz-type plant protease inhibitor and a lectin. We have determined the amino acid sequence and three-dimensional structure of CrataBL, as well as characterized its selected biochemical and biological properties. We found two different isoforms of CrataBL isolated from the original source, differing in positions 31 (Pro/Leu); 92 (Ser/Leu); 93 (Ile/Thr); 95 (Arg/Gly) and 97 (Leu/Ser). CrataBL showed relatively weak inhibitory activity against trypsin (Kiapp = 43 µM) and was more potent against Factor Xa (Kiapp = 8.6 µM), but was not active against a number of other proteases. We have confirmed that CrataBL contains two glycosylation sites and forms a dimer at high concentration. The high-resolution crystal structures of two different crystal forms of isoform II verified the β-trefoil fold of CrataBL and have shown the presence of dimers consisting of two almost identical molecules making extensive contacts (∼645 Å(2)). The structure differs from those of the most closely related proteins by the lack of the N-terminal β-hairpin. In experiments aimed at investigating the biological properties of CrataBL, we have shown that addition of 40 µM of the protein for 48 h caused maximum growth inhibition in MTT assay (47% of DU145 cells and 43% of PC3 cells). The apoptosis of DU145 and PC3 cell lines was confirmed by flow cytometry using Annexin V/FITC and propidium iodide staining. Treatment with CrataBL resulted in the release of mitochondrial cytochrome c and in the activation of caspase-3 in DU145 and PC3 cells.

Indexed as

Amino Acid SequenceCapparaceaeCell DeathCell Line, TumorCrystallography, X-RayDimerizationDrug Screening Assays, AntitumorGlycosylationHumansMaleMolecular StructurePlant LectinsSequence Homology, Amino AcidSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationCrataBLPlant Lectins

Identifiers

PMID23823708
PMCPMC3688800
OpenAlexW1983320616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.